Dasatinib Patent Expiration
Dasatinib is Used for treating protein tyrosine kinase-associated disorders and various types of cancer, including chronic myelogenous leukemia. It was first introduced by Bristol Myers Squibb Co
Dasatinib Patents
Given below is the list of patents protecting Dasatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Phyrago | US11202778 | Amorphous solid dispersions of dasatinib and uses thereof | Jan 22, 2041 | Nanocopoeia |
| Phyrago | US11298356 | Amorphous solid dispersions of dasatinib and uses thereof | Jan 22, 2041 | Nanocopoeia |
| Phyrago | US11324745 | Amorphous solid dispersions of dasatinib and uses thereof | Jan 22, 2041 | Nanocopoeia |
| Sprycel |
US7491725 (Pediatric) | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | Sep 28, 2026 | Bristol Myers Squibb |
| Sprycel | US7491725 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | Mar 28, 2026 | Bristol Myers Squibb |
| Sprycel |
US8680103 (Pediatric) | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | Aug 04, 2025 | Bristol Myers Squibb |
| Sprycel | US8680103 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | Feb 04, 2025 | Bristol Myers Squibb |
| Sprycel |
US6596746 (Pediatric) | Cyclic protein tyrosine kinase inhibitors |
Dec 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel |
US7153856 (Pediatric) | Cyclic protein tyrosine kinase inhibitors |
Oct 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel |
US7125875 (Pediatric) | Cyclic protein tyrosine kinase inhibitors |
Oct 13, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel | US6596746 | Cyclic protein tyrosine kinase inhibitors |
Jun 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel | US7153856 | Cyclic protein tyrosine kinase inhibitors |
Apr 28, 2020
(Expired) | Bristol Myers Squibb |
| Sprycel | US7125875 | Cyclic protein tyrosine kinase inhibitors |
Apr 13, 2020
(Expired) | Bristol Myers Squibb |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasatinib's patents.
Latest Legal Activities on Dasatinib's Patents
Given below is the list recent legal activities going on the following patents of Dasatinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Aug, 2020 | US7491725 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Jun, 2018 | US7153856(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Apr, 2018 | US7125875 |
| Post Issue Communication - Certificate of Correction | 22 Nov, 2011 | US7491725 |
| Email Notification Critical | 03 Aug, 2010 | US7491725 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 28 Jul, 2010 | US7491725 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Allowance | 27 Jul, 2010 | US7491725 |
| Adjustment of PTA Calculation by PTO | 27 Jul, 2010 | US7491725 |
| Court Processing Terminated | 23 Jun, 2010 | US7491725 |
| Decision in Civil Action - Dismissed by Court | 23 Jun, 2010 | US7491725 |
Dasatinib's Family Patents
Explore Our Curated Drug Screens
Dasatinib Generic API Manufacturers
Several generic applications have been filed for Dasatinib.
Given below is the list of companies who have filed for Dasatinib generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 6 different strengths of generic version for Dasatinib. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG | tablet | Prescription | ORAL | AB | Jun 10, 2016 |
| 50MG | tablet | Prescription | ORAL | AB | Jun 10, 2016 |
| 70MG | tablet | Prescription | ORAL | AB | Jun 10, 2016 |
| 100MG | tablet | Prescription | ORAL | AB | Jun 10, 2016 |
| 80MG | tablet | Prescription | ORAL | AB | Nov 23, 2021 |
| 140MG | tablet | Prescription | ORAL | AB | Nov 23, 2021 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||